Filing Flows › CytomX Therapeutics (CTMX) › Q2 2025
CytomX Therapeutics (CTMX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
CytomX Therapeutics (CTMX) reported revenue of $18.7M for the second quarter 2025 (Q2 2025), -26% from a year earlier and -63% from the quarter before. Operating margin was -6.9%, net loss $154K (0.8% of revenue).
CytomX Therapeutics, Q2 2025: revenue $18.7M (-26% year over year), operating margin -6.9%, net loss $154K, operating cash flow −$15.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.7M | -63% | -26% |
| Operating profit | −$1.3M | -106% | — |
| Net earnings | −$154K | -101% | — |
| Operating cash flow | −$15.8M | — | — |
What changed
Revenue was $18.7M in Q2 2025, down 26% year over year and down 63% from the previous quarter.
Operating costs exceeded revenue by $1.3M, an operating margin of -6.9%. Total costs fell 41% while revenue fell 26%. The quarter ended with a net loss of $154K, after a profit of $23.5M the previous quarter. Non-operating items added $1.2M, -1313% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$15.8M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $17.0M. Capital expenditures of $27K exceeded it, leaving free cash flow of −$15.8M.
Questions
What was CytomX Therapeutics' revenue in the second quarter 2025?
CytomX Therapeutics (CTMX) reported revenue of $18.7M for the second quarter 2025 (Q2 2025), -26% from a year earlier and -63% from the quarter before.
Was CytomX Therapeutics profitable in the second quarter 2025?
Operating loss was $1.3M (-6.9% of revenue) and net loss $154K.